Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
CRISPR Therapeutics AG
CRSP
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.4B
$59.30
▲ +6.62%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$44.12 - $78.48
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 7.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CRISPR/Cas9 gene-editing platform
- Advanced pipeline of targeted therapies
- Strategic pharmaceutical partnerships
- Breakthrough technology with broad applications
Bear Case
1 risk
- Above-average volatility (beta 1.7).
Growth
Strong growth ahead
Expanding gene therapy market
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+12.3% over 3m
Quality
Mixed
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CRSP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 11, 2026
MAY 5, 2026
Reported EPS of -$1.28 vs -$1.22 consensus (-5.0% surprise). Revenue of $1.5M vs $6.1M expected (-76.0%).
EPS surprise · last 4Q
0 of 2 beats
Q2 26
-5.0%
Q2 26
-5.0%
Next: May 11, 2026
Revenue trend · last 8Q
—
—
-83%
+72%
+73%
—
-98%
+69%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$517.0K
$0
$35.0M
$865.0K
$892.0K
$889.0K
$864.0K
$1.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
-8431.5%
Wall Street consensus
8 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
$66.00
▲ +11.3% vs $59.30
Latest: Bernstein · $56.00 · May 13, 2026
2 analysts covering